Impact and management of COVID-19 in liver transplant candidates and recipients

Christina Liava; Konstantinos Ouranos; Anthi Chatziioannou; Irene Kamenidou; Athanasios Kofinas; Stella Vasileiadou; Nikolaos Antoniadis; Georgios Katsanos; Evangelos Akriviadis; Emmanouil Sinakos

Authors Christina Liava, Konstantinos Ouranos, Anthi Chatziioannou, Irene Kamenidou, Athanasios Kofinas, Stella Vasileiadou, Nikolaos Antoniadis, Georgios Katsanos, Evangelos Akriviadis, Emmanouil Sinakos.

Abstract

The COVID-19 outbreak has had severe consequences for global public health, medical communities, and the socioeconomic status of a considerable number of countries. The emergence of COVID-19 has also significantly impacted the world of liver transplantation (LT). Studies from transplantation centers around the world have shown that LTs during the COVID-19 pandemic have been restricted because of the high risk of serious COVID-19 infection in this population. According to the Centers for Disease Control and Prevention, patients with liver disease are considered at higher risk for severe COVID-19 infection. In March 2020, the American Association for the Study of Liver Diseases recommended that LT should be limited to emergency cases. The COVID-19 treatment guidelines published by the National Institutes of Health are being constantly updated according to new epidemiology trends and treatment regimens. Immunocompromised patients have a higher risk of developing severe disease or death from COVID-19 compared with the general population. In this review, we summarize the available evidence regarding treatment guidelines and considerations for the evaluation and anagement of LT candidates and recipients in the era of COVID-19. In addition, we present data regarding COVID-19 among LT patients in our local transplantation center.

Keywords COVID-19, SARS-CoV-2, liver transplantation, chronic liver disease, vaccination

Ann Gastroenterol 2023; 36 (5): 477-489